The text starts here.

News Release

November 25, 2005
For Print (PDF 11KB)

Termination of Marketing Alliance on Rulid(R) Tablets 150mg

sanofi-aventis Group Japan
Eisai Co., Ltd.

Sanofi-aventis Group Japan (hereafter: sanofi-aventis, Headquarters: Tokyo, President: Philippe Fauchet) and Eisai Co., Ltd. (hereafter: Eisai, Headquarters: Tokyo; President & CEO: Haruo Naito) announced today that they have reached an agreement to terminate the marketing alliance on December 31, 2005 for Rulid(R) Tablets 150mg (generic name: roxithromycin), a long-acting macrolide marketed by Eisai under license from sanofi-aventis. Sanofi-aventis will market the drug from January 1, 2006.

Rulid(R) Tablets 150mg is an oral antibiotic of the macrolide class, discovered by Roussel Uclaf (now sanofi-aventis). Rulid(R) taken twice daily reaches therapeutic concentrations in the blood and has good tissue penetration. It has shown favorable efficacy against acne (pimples), skin infections, sinusitis, otitis media, respiratory tract infections and dental infections.

Media Relations Communication
sanofi-aventis Group Japan
Tel : +81-3-6301-4148
Corporate Communications Department
Eisai Co., Ltd.
Tel : +81-3-3817-5120